An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
Week of February 13, 2023
|
|
|
Moores Cancer Center & Cancer Services Town Hall
Monday, February 13 from 4:00 to 5:00 p.m.
Goldberg Auditorium and via Webinar
As a community dedicated to serving those with cancer, those at risk for cancer, and defining novel and innovative ways to prevent and treat cancer in our community, we are so fortunate to have the opportunity to lead in San Diego County and throughout the world.
We will be sharing some of the results of our recent collaborative strategic planning process for Moores Cancer Center, our UCSD Cancer Service strategic plan, as well as other updates that advance this mission.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
ODAC gives thumbs-up to GSK plan to build on MSK rectal cancer study of dostarlimab that produced 100% response
Read full article on page 5 of The Cancer Letter, volume 49 number 6.
Biden places cancer in top spot on Unity Agenda; announces new Moonshot programs
Read full article on page 28 of The Cancer Letter, volume 49 number 6.
|
|
|
|
DRM Seminar Series
Regenerative Strategies Using mRNA Technology
Monday, February 13, 2023 from 3:00 to 4:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Zoom Link available upon request
Panteleimon Rompolas, M.B.A., Ph.D.
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania
Hosted by Shiri Gur-Cohen, Ph.D.
|
|
|
|
Pharmacology Seminar Series
Interorgan Communication Through Plasmalipid Signaling
Tuesday, February 14, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Judith Simcox, Ph.D.
Assistant Professor
Department of Biochemistry
University of Wisconsin-Madison
Hosted by Susan Taylor, Ph.D. and Alan Saltiel, Ph.D.
|
|
|
|
Cancer Biology and Signaling Seminar Series
Engineered Native Bacteria and their Potential Use as a Cancer Therapeutic
Wednesday, February 15, 2023 at 12:00 p.m. PT
Comer Commons
Lunch will be provided
Optional Webinar Registration
Amir Zarrinpar, M.D., Ph.D.
Assistant Professor, Gastroenterology
|
|
|
|
Pharmacology Seminar Series
Mechanotransduction in vascular homeostasis and pathological conditions
Tuesday, February 21, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building Room 107
Optional Webinar Registration
Luisa Iruela-Arispe, Ph.D.
Professor and Chair, Department of Cell and Developmental Biology
Stephen Walter Ranson Professor of Cell Biology
Northwestern University - Feinberg School of Medicine
Hosted by: J. Silvio Gutkind, Ph.D.
|
|
|
|
Cancer Control Program Work In Progress Seminar Series
Integrating “When to Eat” and “Who Should Eat” and Concepts to Evaluate Inflammatory Foods
Wednesday, March 1, 2023 at 12:00 p.m. PT
MCC Comor Commons Conference Room
Lunch provided, beginning at 11:30 a.m.
Optional Webinar Registration
Tianying Wu, Ph.D.
Associate Professor
San Diego State University, School of Public Health
Division of Epidemiology and Biostatistics
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
San Diego Colorectal Cancer Screening Roundtable
Thursday, February 22, 2023 from 10:00 a.m. to 12:00 p.m.
Join us for information on the current state of colorectal cancer screening in San Diego, upcoming changes in Medi-Cal, emerging screening tests, and how we can increase screening to get back on track.
This roundtable is designed for medical directors, clinicians, quality improvement staff, panel managers, project managers, and health center staff to hear and share best practices on improving colorectal cancer screenings in San Diego County.
|
| |
Make San Diego HPV Cancer Free
Monday, February 27, 2023 from 10:00 a.m. to 11:30 a.m. PT
etween 2020-2022, approximately 120,000 fewer 11-to-13-year-olds in California began their HPV vaccine series, as compared to pre-pandemic levels in 2019 (California Immunization Registry). It is as critical as ever to catch up our kids on their cancer prevention!
Please join SD PATH, a workgroup of Moores Cancer Center at UC San Diego Health, for our 3rd Annual 'Make SD HPV Cancer Free' Summit on February 27th, 2023. This meeting will focus on:
|
- Local and State HPV Vaccination Rates
- The Case for Age 9 HPV Vaccination Promotion
-
SD PATH Partnership Spotlights: Success Stories and Future Promise of HPV
- Vaccination Interventions in SD County
|
|
|
Student Volunteers Available
MCC CRTEC has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu, if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Prostate Cancer Foundation (PCF) 2023 Young Investigator Awards Request for Letters of Intent and Full Applications
Award: $75,000 per year for 3 years
The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. For example, this includes funding "protected time" or direct costs for laboratory science. This award does not support indirect costs, such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of one to three mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
LOI Deadline: February 10, 2023 by 3:00 p.m. ET
Submission Portal Opens: Monday, February 27, 2023
Invited Full Application Deadline: Monday, April 24, 2023 by 3:00 p.m. ET
Questions? Contact LettersofIntent@pcf.org.
|
| |
Call for LOIs: Cancer Immunology, Innovators in Science Award
MCC is soliciting LOIs for the limited-submission Innovators in Science Award, administered by the New York Academy of Sciences and sponsored by Takeda. This award recognizes the contributions of an Early-Career Scientist and a Senior Scientist to biomedical science and is intended to support their commitment to innovative research. These are independent awards; the early-career and senior scientists do not need to work together.
This year’s theme is Cancer Immunology, with seven eligible subcategories.
2024 Award Subcategories in Cancer Immunology
|
-
Emerging immunomodulatory therapeutics
- Innate immunity as a therapeutic approach
- Immune mechanisms in the tumor microenvironment
- Next-generation cell-based therapeutics
- Epigenetic immune regulation in cancer
- Precision and translational medicine approaches to individualized immunotherapies
- Other
|
UCSD is limited to two nominations (one early-career scientist AND one senior scientist; nominees must be UCSD faculty members). One prize will be given at each level, with individual prizes worth $200K. Details on eligibility, nomination requirements, and evaluation criteria, along with FAQs, are available at the link above.
To be considered for nomination, please send a 1-page LOI to aballantyne@health.ucsd.edu for review by our grants committee. LOI instructions appear below; the links above provide detailed information on the awards.
All LOIs must be submitted to Angela Ballantyne, Ph.D. (aballantyne@health.ucsd.edu) in a single PDF by the internal deadline of Monday, February 13, 2023 at 5:00 p.m. Follow these instructions for the submission of your single PDF, which contains both 1 and 2 below:
|
- Letter providing strong rationale for nomination (1 page maximum)
-
Arial, at least 11 point font, at least 1/2 inch margins all around, 1 page maximum, including any figures, tables, etc. Citations only may be included on a second page.
- Include your name, degree(s), title, department, phone number, email address; the specific award (early-career or senior scientist), statement of eligibility per the published guidelines.
-
Briefly describe your strong record of significant independent scientific contributions, career success, and promise of sustained or accelerated progress in the future; address the quality, impact, novelty, and promise of your research)
- NIH-style biosketch
- 5 pages max; include active and pending support
-
Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
|
|
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase
Through this FOA, the NCI intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects: Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners should be made between October 2022 and November 2022.
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
Tina’s Wish Rising Star Grant Opportunity: 2024-25
The Honorable Tina Brozman Foundation (“Tina’s Wish”) will be releasing our RFP for the Rising Star Grants for 2024-25. In order to plan appropriately, we are requiring that all those interested in applying for this grant take 30 seconds to submit a Rising Star Grant Intent to Apply form. Click here to learn more about Tina’s Wish.
Grant Objective:
Tina’s Wish is committed to supporting early career researchers who bring fresh approaches to the study of the early detection or prevention of ovarian cancer. The goal is to assist and support promising researchers in the ovarian cancer field and to encourage them to take risks and develop innovative projects.
Please note that the Rising Star Grants are separate and distinct from the Team Science Grants. The Rising Star Grant is funded at $75,000/year for two (2) years, total grant award: $150,000.
Please click here to access the Intent to Apply form. Applicants must complete the Intent to Apply form by Wednesday, March 1st, 12pm ET in order to receive the link to submit a full proposal. The full RFP will be sent once the Intent to Apply form has been submitted. The full proposals will be due on or before Monday, April 17th, 12pm ET.
Eligibility and Selection Criteria (applicants must meet ALL the criteria listed)
|
- Applicants must be working in a school of medicine or public health, or a recognized non-profit scientific research facility in the United States.
-
Applicants must have a committed mentor to support the applicant throughout the grant period. One’s mentor does not need to be at the same institution as the applicant, provided that the mentor is committed to a meaningful and productive mentorship relationship throughout the grant period.
-
Please note that if one’s current mentor is not connected to the ovarian cancer research community, please seek out a mentor that is a subject matter expert in the ovarian cancer field. If you need assistance in securing such a mentor, please let Tina’s Wish know (this will not be considered a negative when reviewing your proposal).
- The research project for which support is requested should be innovative and not currently funded.
- Applicants should hold a PhD, MD, or MD, PhD degree.
-
PhD applicants must be within three years of completing their degree and be at the postdoctoral level of training or similar (a non-tenured level position) when the grant begins in January, 2024. If one is at the Instructor level, one is eligible to apply for this grant if one’s lab is embedded in a more senior/established lab; if at the Instructor level and as an independent lab, please review the Team Science Grant opportunity).
-
MD or MD, PhD applicants must be at the instructor or assistant professor level (or a similar faculty position) and within three years of starting their first faculty appointment at the time of the estimated award date (January 2024). Note: Clinical or research fellows with dedicated research time for the two years of the Rising Star Grant funding period (January 2024-December 2025) will also be eligible. Fellows should include a letter of institutional commitment of at least 75% research time for the Rising Star Grant funding period with their application.
- Note: Prevention studies should be focused on early cancer interception and include chemoprevention strategies.
|
Deadline: Wednesday, March 1, 2023
|
|
|
SITC Fellowships: Funding Opportunities for Early Career Scientists
The Society for Immunotherapy of Cancer (SITC) is committed to assisting young investigators in advancing the science of immunotherapy. This year, the SITC Forward Fund is pleased to offer four SITC Fellowships, totaling $440,000 in funding. Get started on your application now! Submissions are due by March 27, 2023.
SITC Fellowships are only available to SITC members. Not a member? Sign up today.
Deadline: Monday, March 27, 2023
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, M.P.H., M.B.A. at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multi-center UCHMC interventional clinical trials. Funding may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as it see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
Call for Applications to Fund Travel to Scholarly Meeting for FY 2022/23, Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
Applications may be submitted throughout the year but must be received and approved prior to the conference start date. Applications will be reviewed while funds are available. Funds will not be awarded retroactively.
Any UCSD Health Sciences (HS) Clinical series faculty member holding an M.D. or D.O. can receive one trip every other fiscal year (July 1-June 30). Travel awards (domestic or foreign) will be made for a maximum of $750 toward standard economy airfare and/or registration fees (documentation required).
Eligibility is to HS Clinical series faculty who (1) have an accepted abstract to a scientific professional society conference, (2) are not a member of the Academic Senate, and (3) are either the first or senior author on the abstract podium or poster presentation of original clinical research. Invited lectures, workshops, or panel or moderator invites are ineligible and will not be considered.
|
|
|
Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
R01 Award: Maximum duration is 5 years. For over $500,000/year in direct costs, NIH approval is required.
R21 Award: Combined budget for direct costs for the 2-year maximum project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
NCI Program Project Applications for 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Award: Application budgets are not limited yet must reflect the actual needs of the proposed project. The project period may not exceed 5 years.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
DoD Fiscal Year 2023 (FY23) Breast Cancer Research Program (BCRP), and Peer Reviewed Medical Research Program (PRMRP) funding opportunities.
Transformative Breast Cancer Consortium Award
|
- Breast Cancer Research Program
- Transformative Breast Cancer Consortium Award
- **NEW for FY23** Transformative Breast Cancer Consortium Development Award
- Clinical Research Extension Award
- Breakthrough Award Levels 1 and 2
- Breakthrough Award Level 3
- Breakthrough Award Level 4
- Era of Hope Scholar Award
- Innovator Award
|
Peer Reviewed Medical Research Program
|
- Clinical Trial Award
- Discovery Award
- Focused Program Award
- Investigator-Initiated Research Award
- Lifestyle and Behavioral Health Interventions Research Award
- Technology/Therapeutic Development Award
|
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions which can be found on the Grants.gov website (https://Grants.gov).
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer.
This notice applies to due dates on or after January 5, 2023, and subsequent receipt dates through July 2, 2025. You may submit applications for this initiative using any of the 30 FOAs listed on the website below or any reissues of these announcement through the expiration date of this notice.
The purpose of this NOSI is to solicit applications directed toward (1) identifying, characterizing, and mitigating risk factors and (2) identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.
|
|
|
Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
This NOSI informs current awardees that the NCI is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma (as defined below), assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries (LMICs).
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
Notice of Special Interest (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute.
This notice applies to due dates on or after February 12, 2023, and subsequent receipt dates through November 13, 2024. You may submit applications for this initiative using any of the fifteen funding opportunity announcements (FOAs) listed on the website below, or any reissues of these announcement through the expiration date of this notice.
This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.
Research Objectives
Priority research areas for DCP include but are not limited to:
|
- Cancer Prevention/ Interception
- Cancer Early Detection/ Screening
- Symptom Science
|
|
|
Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research.
This notice applies to due dates on or after March 01, 2023 and subsequent receipt dates through the expiration date of this notice.
The purpose of this NOSI is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population-scale omics research, with the goal of driving innovation in this field.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT Data and Resource Coordination Center will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
RFA – Aging & Cancer Research with The Mark Foundation
Awards will provide $500,000 total over three years ($250,000 to each PI).
Deadline: March 1, 2023 at 5:00 p.m.
|
| RFA – Aging & Cancer Research with The Israel Cancer Research Fund
Two collaborative projects will be funded; each project will be awarded $200,000 per year for 2 years, or a total of $400,000, with each research group receiving $100,000 per year ($200,000 total); successful projects may be eligible for a third year of funding at the level of $100,000 ($50,000 per research group).
LOI Deadline: March 1, 2023 at 5:00 p.m.
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
|
|
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
| |
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
See website for more details about CT2 program: WEBSITE
|
- Complete CT2 program application (form available to download from the website above)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact
Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
Deadline: March 15, 2022
|
| |
American Association for the Study of Liver Diseases (AASLD), Harold Amos Medical Faculty Development Program (AMFDP) Award Opportunity
Applications Available: February 8, 2023
Application deadline: March 16, 2023
As part of AASLD's efforts to advance our shared goal of cultivating the next generation of academic leaders, AASLD has partnered with the AMFDP of the Robert Wood Johnson Foundation (RWJF). The program has been designed to increase the number of scholars from historically marginalized groups in the field of hepatology with academic and research appointments. The AASLD-AMFDP Award offers 4 years of postdoctoral research support to historically disadvantaged physicians who are committed to developing careers in academic medicine and serving as role models for students and faculty of similar backgrounds.
About the AASLD-AMFDP (Harold Amos Award)
For over 20 years, RWJF has worked to increase the representation of minority scholars in academic medicine through its AMFDP, which was created to assist faculty from historically disadvantaged backgrounds to achieve senior rank in academic medicine. The AMFDP is named after Harold Amos, Ph.D., who was the first African-American to chair a department (now the Department of Microbiology and Medical Genetics) at Harvard Medical School.
The AASLD Governing Board recently approved support for the program to strengthen its commitment to diversity, equity, and inclusion efforts in hepatology. Through the program, AASLD is committed to funding one AMFDP hepatology scholar for 4 years. The selected scholar (1) is expected to spend at least 70 percent of his or her time on research activities, in association with a senior faculty member located at an academic medical center and (2) will receive an annual stipend of up to $75,000, complemented by a $30,000 annual grant toward support of research activities.
Program Mentorship
The selected awardee will be assigned a National Advisory Committee mentor, following an application review and an in-person interview, who will follow his or her progress throughout the award term and provide additional guidance.
The selected cohort will meet for mentoring and leadership training.
Eligibility Requirements
To be eligible for this award, the applicant must meet the following requirements:
|
-
Physician or nurse from a historically disadvantaged background (ethnic, financial, or educational) who has excelled in his or her education
- U.S. citizen or permanent resident at the time of the application deadline
- Completing or have completed formal clinical training
- Prepared to devote 4 consecutive years to research
-
Committed to pursuing an academic career and improving the health status of the underserved, decreasing health disparities, or serving as a role model for students and faculty from historically disadvantaged backgrounds.
|
Application Process
To view detailed application requirements and begin the application process, please visit the AMFDP website.
|
|
|
Scientist Solutions Life Science Vendor Show
Thursday, February 23, 2023 from 12:00 p.m. to 1:30 p.m.
Comer Commons Conference Room
Pre Register Now To Guarantee Your Lunch Selection And Be Entered into our special drawing for a $25 Amazon Gift Card or Bluetooth Speaker!
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Solid Tumor Therapeutics Program Retreat
Friday, March 3, 2023 from 9:00 a.m. to 4:30 p.m.
UCSD MCC Goldberg Auditorium
The retreat will include catered breakfast and lunch.
|
|
|
Luis Diaz, M.D.
Grayer Family Chair Head, Division of Solid Tumor Oncology Professor, Weill Cornell Medical School
|
|
Lisa Butterfield, Ph.D.
Adjunct Professor of Microbiology and Immunology
University of California, San Francisco
|
|
|
Additional Speakers Include
Sonia Sharma, Ph.D. Anandra W. Goldrath, Ph.D. Liangfang Zhang, Ph.D. Nicole Steinmetz, Ph.D. Shweta Joshi, Ph.D. Tariq Rana, Ph.D. Rebekah White, M.D., FACS Rebecca Shatsky, M.D.
|
|
|
Structural and Functional Genomics Program Retreat
Friday, May 5, 2023
UCSD MCC Goldberg Auditorium and Lobby
The retreat will include breakfast and lunch.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head & Neck Cancer Center
Professor, Department of Otolaryngology/Head & Neck Surgery, UCSD, School of Medicine
Co-Leader, MCC, Structural and Functional Genomics Program
|
|
Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences Professor, Department of Medicine, UCSD School of Medicine Co-Leader, MCC Structural and Functional Genomics Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
| Clinical Trials Office (CTO), Staff of the Month: Kayleigh Hernandez
Kayleigh has been with the Head and Neck Team for over 2 years and exhibits commendable dedication to it. She never hesitates to offer a helping hand to other coordinators to ensure that they receive the support they need. Kayleigh goes above and beyond by providing coordinators with informative and detailed trainings to address common challenges, which include tissue retrieval/biopsies, single patient INDs, and how to prepare for new studies. She looks for new ways to improve processes and has even helped our team further develop our on-boarding and training process for new coordinators. Kayleigh is really passionate about Head and Neck Clinical Trials and is a great role model for our team with her positive attitude. She shows up each day, always ready to give 100%. The CTO and Head and Neck Team are very grateful to have Kayleigh as a member!
|
|
|
Newly Opened Clinical Trials
|
|
|
66169 - Tecartus Collaborative Study: Outcomes in Adult B-Cell Acute Lymphoblastic Leukemia After Commercial CART Therapy (Brexucabtagene Autoleucel) as an FDA-approved Therapy
PI: Koura, D
NCT: Not in CT.gov
|
| | |
|
BCA101X1101: First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF Fusion Protein BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
PI: Sacco, A
NCT: NCT04429542
|
| | |
|
VAR-2021-04: Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Phase II Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)
PI: Mayadev, J
NCT: NCT05197881
|
| | |
|
MK-6482-022-00: A Multicenter, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK6482) plus Pembrolizumab (MK 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482022)
PI: McKay, R
NCT: NCT05239728
|
| | |
|
SHARED RESOURCE SPOTLIGHT
|
| |
New Community Outreach Partnership with El Centro Regional Medical Center (ECRMC)
On December 15, 2022, the El Centro Regional Medical Center (ECRMC) Multidisciplinary Research Council (MRC) approved a collaborative project with the MCC Biorepository and Tissue Technology Shared Resource (BTTSR), a College of American Pathologists (CAP)-accredited core. This project will support biospecimen procurement at ECRMC, with the main purpose of bridging the gap in the participation in research by populations with health disparities.
For more details, please contact BTTSR at skaushal@health.ucsd.edu
|
|
|
Biostatistics Shared Resource (BSR)
The MCC BSR not only provides comprehensive biostatistics and data analytics collaboration and support, but also is happy to help with grant and protocol development.
The BSR, established in 1995, currently comprises six faculty members and two staff biostatisticians. Together, BSR faculty and staff support best practices in data analysis and statistical inference; reproducible research; clinical trial design, reporting and analysis; causal inference from observational studies; and statistical methodology.
MCC members are not charged for BSR consulting during proposal preparation and early clinical trial protocol development. The BSR's MCC funding is intended for development of long-term collaboration that leads to not only foundation, federal, and industry funding, but also high-profile publications. The BSR also welcomes short consultation requests. Funded projects are expected to incorporate a budget for adequate biostatistics support, which often strengthens grant applications.
The BSR encourages early interaction during proposal planning. For standard proposal development, the BSR needs 4 weeks' advanced notice to review aims, methods, and preliminary results. The BSR can provide not only statistical sections, which include sample size, power calculations, and analysis methods, but also targeted biosketches and letters of support for grant proposals. The BSR recommends contacting the BSR Manager at least 8 weeks in advance for more complex multi-PI, multi-institution, multi-project proposals.
Early interaction during clinical trial development is encouraged. The BSR will provide not only sample size, power calculations, and justifications for any interim safety and/or efficacy analysis, but also randomization plans. During trial operation, the BSR can provide DSMB and regulatory reports, in addition to interim safety and/or final efficacy analysis. The BSR requires negotiated approval of trial budget prior to undertaking these activities.
Please feel free to contact the BSR, which aims to respond within 2 days with a consultation plan. Email Emily Pittman, Ph.D., BSR Manager at eipittman@health.ucsd.edu.
|
|
|
-
Shankara Narayanan JS, Hayashi T, Erdem S, McArdle S, Tiriac H, Ray P, Pu M, Mikulski Z, Miller A (STT), Messer K (CCP), Carson D (HEM), Schoenberger S (STT), White RR (STT). Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer. 2023 JAN 01.
-
Wu C, Rakhshandehroo T, Wettersten HI (STT), Campos A, von Schalscha T, Jain S, Yu Z, Tan J, Mose E, Childers BG, Lowy AM (STT), Weis SM, Cheresh DA (STT). Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat Cell Biol. 2023 JAN 16.
- Yang X, Xu X, Breuss MW, Antaki D, Ball LL, Chung C, Shen J, Li C, George RD, Wang Y, Bae T, Cheng Y, Abyzov A, Wei L, Alexandrov LB (SFG), Sebat JL, Gleeson JG. Control-independent mosaic single nucleotide variant detection with DeepMosaic. Nat Biotechnol. 2023 JAN 02.
-
Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez E (CCP), Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 JAN 09.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|